Doctors track Long-Term effects of hemophilia drug over nearly a decade
NCT ID NCT03745924
Summary
This study will monitor the long-term safety and effectiveness of a preventative treatment (Refixia/REBINYN) for males with hemophilia B. Over 4-9 years, researchers will track side effects, bleeding episodes, and how well the drug controls bleeding during surgery or injuries. Participants will also complete questionnaires about their physical activity and quality of life while receiving their standard treatment.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes NO responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for HAEMOPHILIA B are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Locations
-
"Laiko" General Hospital of Athens
Athens, 11527, Greece
-
"Laiko" General Hospital of Athens
Athens, GR-11527, Greece
-
AKH - Klin. Abt. f. Haematologie u. Haemostaseologie
Vienna, 1090, Austria
-
Aberdeen Royal Infirmary - Haematology
Aberdeen, AB25 2ZN, United Kingdom
-
Aghia Sophia Childrens' Hospital
Athens, GR-11527, Greece
-
CancerCare Manitoba
Winnipeg, Manitoba, R3E 0V9, Canada
-
Cliniques universitaires Saint-Luc - Service Hématologie
Brussels, 1200, Belgium
-
FN Brno odd. hematologie
Brno, 625 00, Czechia
-
Fakultni nemocnice Plzen - Lochotin
Pilsen, 304 60, Czechia
-
Hamilton Health Sciences Corp, Ontario
Hamilton, Ontario, L8N 3Z5, Canada
-
Hamltn Hth Sci/McMstr Child Hosp
Hamilton, Ontario, L8N 3Z5, Canada
-
Health Science Centre
St. John's, Newfoundland and Labrador, A1B 3V6, Canada
-
Helsinki University Central Hospital/Coagulation Disorder Un
Helsinki, 00290, Finland
-
Hospital São José
Lisbon, 1150-199, Portugal
-
KBC Zagreb, Rebro, Hemofilija centar
Zagreb, 10 000, Croatia
-
Klinisk forskningspost
Oslo, 0372, Norway
-
Royal Hallamshire Hospital
Sheffield, S10 2JF, United Kingdom
-
Royal Manchester Children's Hospital
Manchester, M13 9WL, United Kingdom
-
Skejby Blodsygdomme, blødercentret
Aarhus N, 8200, Denmark
-
The Hospital for Sick Children
Toronto, Ontario, M5G 1X8, Canada
-
UZ Antwerpen - UZA - Kinderhemato-Oncologie
Edegem, 2650, Belgium
-
UZ Leuven - Hart en Vaatziekten
Leuven, 3000, Belgium
-
Unidade Local de Saúde São José EPE- Hospital D. Estefânia
Lisbon, 1169-045, Portugal
-
Univ of Alberta Hospital Res
Edmonton, Alberta, T6G 2V2, Canada
-
University Hospital of Wales - Haemophilia
Cardiff, CF14 4XW, United Kingdom
-
University of Calgary Cumming School of Medicine
Calgary, Alberta, T2N 2T9, Canada
-
Universitätsklinikum Bonn - Institut für Experimentelle Hämatologie
Bonn, 53127, Germany
-
Universitätsspital Zürich - Klinik für Medizinische Onkologie und Hämatologie
Zurich, 8091, Switzerland
-
Vivantes Netzwerk für Gesundheit GmbH - Vivantes Klinikum im Friedrichshain
Berlin, 10249, Germany
Conditions
Explore the condition pages connected to this study.